Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.
Chiappa M, Decio A, Guarrera L, Mengoli I, Karki A, Yemane D, Ghilardi C, Scanziani E, Canesi S, Barbera MC, Craparotta I, Bolis M, Fruscio R, Grasselli C, Ceruti T, Zucchetti M, Patterson JC, Lu RA, Yaffe MB, Ridinger M, Damia G, Guffanti F. Chiappa M, et al. Among authors: guffanti f. Cell Death Dis. 2024 Jul 22;15(7):521. doi: 10.1038/s41419-024-06894-1. Cell Death Dis. 2024. PMID: 39039067 Free PMC article.
Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair.
Ganzinelli M, Guffanti F, Ianza A, Sobhani N, Crovella S, Zanconati F, Bottin C, Confalonieri M, Fumagalli S, Guglielmi A, Generali D, Damia G. Ganzinelli M, et al. Among authors: guffanti f. Cancers (Basel). 2023 Aug 29;15(17):4309. doi: 10.3390/cancers15174309. Cancers (Basel). 2023. PMID: 37686585 Free PMC article.
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
La Verde N, Damia G, Garrone O, Santini D, Fabi A, Ciccarese M, Generali DG, Nunzi M, Poletto E, Ferraris E, Cretella E, Scandurra G, Meattini I, Bertolini AS, Cavanna L, Collovà E, Romagnoli E, Rulli E, Legramandi L, Guffanti F, Bramati A, Moretti A, Cassano A, Vici P, Torri V, Farina G; PAINTER investigators. La Verde N, et al. Among authors: guffanti f. Breast Cancer Res. 2022 Oct 28;24(1):71. doi: 10.1186/s13058-022-01560-w. Breast Cancer Res. 2022. PMID: 36307826 Free PMC article. Clinical Trial.
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment.
Chiappa M, Petrella S, Damia G, Broggini M, Guffanti F, Ricci F. Chiappa M, et al. Among authors: guffanti f. Front Oncol. 2022 Jun 2;12:903016. doi: 10.3389/fonc.2022.903016. eCollection 2022. Front Oncol. 2022. PMID: 35719948 Free PMC article. Review.
Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas.
Affatato R, Chiappa M, Guffanti F, Ricci F, Formenti L, Fruscio R, Jaconi M, Ridinger M, Erlander M, Damia G. Affatato R, et al. Among authors: guffanti f. Ther Adv Med Oncol. 2022 May 31;14:17588359221095064. doi: 10.1177/17588359221095064. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35665077 Free PMC article.
31 results